Finding newborns at higher risk of type 1 diabetes for prevention studies
Identifies newborns with higher genetic risk of type 1 diabetes for prevention trials.
Plain-language title generated from the registry record
Registry title: M1no-Study - Early Identification of Infants With High Type 1 Diabetes Risk for Participation in Primary Prevention Trials
Key facts
- Where
- Lecco, Milan, Novara, and Varese, ItalySee the 5 sites
Where in Italy
- ASST Lecco - Ospedale ManzoniLecco, ItalyNo longer taking part
- Clinica MangiagalliMilan, ItalyNo longer taking part
- IRCCS Ospedale San RaffaeleMilan, ItalyNo longer taking part
- A.O.U. Maggiore della Carità di NovaraNovara, ItalyNo longer taking part
- Ospedale Filippo del PonteVarese, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele
- Trial code
- NCT07670143
- Record updated
- 26 June 2026
- Original description
The goal of this observational study is to identify newborns at increased genetic risk of developing type 1 diabetes-specific beta-cell autoantibodies in order to determine eligibility for participation in primary prevention randomized controlled trials aimed at preventing beta-cell autoimmunity.Read full original descriptionShow less
Identification of Infants With Increased Type 1 Diabetes Risk for Enrollment Into Primary Prevention Trials.
The goal of this observational study is to identify newborns at increased genetic risk of developing type 1 diabetes-specific beta-cell autoantibodies in order to determine eligibility for participation in primary prevention randomized controlled trials aimed at preventing beta-cell autoimmunity.
Inclusion: Screening is performed between the ages of 0 and 6 weeks; Consent form signed by parents/guardian.
Exclusion: Infants aged above 6 weeks; Refusal to participate in the study.